Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Autor:
Paolo Veronesi, Matteo Puntoni, Aliana Guerrieri-Gonzaga, Bernardo Bonanni, Giuseppe Viale, Paolo Bruzzi, Alessandra Gennari, Massimiliano Cazzaniga, Harriet Johansson, Fabio Bassi, Valentina Aristarco, Davide Serrano, Clara Varricchio, Giancarlo Pruneri, Viviana Galimberti, Matteo Lazzeroni, Alberto Luini, Andrea Decensi, Maria Stella Trabacca
Publikováno v:
Journal of Clinical Oncology. 30:2593-2600
Purpose Metformin is associated with reduced breast cancer risk in observational studies in patients with diabetes, but clinical evidence for antitumor activity is unclear. The change in Ki-67 between pretreatment biopsy and post-treatment surgical s
Autor:
Eleftherios P, Mamounas, Ann, Brown, Stewart, Anderson, Roy, Smith, Thomas, Julian, Barbara, Miller, Harry D, Bear, Christopher B, Caldwell, Alonzo P, Walker, Wendy M, Mikkelson, Jay S, Stauffer, Andre, Robidoux, Heather, Theoret, Atilla, Soran, Atilla, Sovan, Bernard, Fisher, D Lawrence, Wickerham, Norman, Wolmark
Publikováno v:
Journal of Clinical Oncology. 23:2694-2702
Purpose Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy. Patients and Methods
Autor:
David A. Taber, Christopher W. Ryan, Nancy B. Davis, Everett E. Vokes, Rafat Ansari, Nicholas J. Vogelzang, Christopher George, Walter M. Stadler
Publikováno v:
Journal of Clinical Oncology. 22:115-119
Purpose Determine response rate, time to disease progression, and toxicity of the proteasome inhibitor PS-341 in patients with stage IV renal cell cancer. Patients and Methods PS-341 1.5 mg/m2 was administered intravenously twice weekly for 2 weeks e
Autor:
James Perry, Warren P. Mason, Wolfgang Wick, J. Gregory Cairncross, Enrico Franceschi, Christopher J. O'Callaghan, Normand Laperriere, Ryo Nishikawa, Wilson Roa, Florence Laigle-Donadey, Chad Winch, Olivier Chinot, Johan Menten, David Osoba, Michael Fay, Claire Phillips, Alba A. Brandes, Arjun Sahgal, Keyue Ding, Hal W. Hirte
Publikováno v:
Journal of Clinical Oncology. 34:LBA2-LBA2
LBA2 Background: The EORTC (26981-22981)/NCIC CTG (CE.3) RCT in newly diagnosed glioblastoma (GB) showed increased overall survival (OS) with concomitant and adjuvant temozolomide (TMZ) added to radiotherapy (RT). Pts were 18-71 (median 56) years; ho
Publikováno v:
Journal of Clinical Oncology. 8:1525-1530
To evaluate the effect of dactinomycin (AMD) dose and schedule on the frequency of severe hepatic toxicity in unirradiated National Wilms' Tumor Study-4 (NWTS-4) patients, we reviewed the records of 154 children randomized to single-dose AMD and 176
Autor:
Kathleen I. Pritchard, Karen A. Gelmon, Patricia A. Ganz, Vuk Stambolic, Bingshu E. Chen, Julie Lemieux, Dawn L. Hershman, Jennifer A. Ligibel, IA Mayer, Pamela J. Goodwin, Timothy J. Hobday, Priya Rastogi, Timothy J. Whelan, Wendy R. Parulekar, Lois E. Shepherd, C. Elliott
Publikováno v:
Journal of Clinical Oncology. 29:TPS103-TPS103
TPS103 Background: There has been a recent convergence of epidemiologic, clinical and preclinical evidence suggesting metformin (a biguanide used to treat type 2 diabetes) may lower BC risk and improve BC outcomes. This evidence raises the intriguing